Pomerantz Law Firm Probes Possible Securities Fraud Against Summit Therapeutics Inc.

Pomerantz LLP, a law firm renowned for its representation of investors, has announced it is investigating claims on behalf of the shareholders of Summit Therapeutics Inc. (NASDAQ: SMMT). The crux of this investigation revolves around allegations of potential securities fraud and other unlawful business practices that may have been committed by Summit and some of its top executives.

On May 30, 2025, Summit released a statement detailing the topline results from its Phase III clinical trial named HARMONi, the world's first evaluation of ivonescimab. Although the treatment combined with chemotherapy showed that patients had a 48% lower risk of disease progression or mortality compared to those only receiving chemotherapy, the drug did not produce a statistically significant difference in overall survival rates—the key metric determining a treatment's effectiveness in prolonging life.

This disappointing news significantly impacted Summit's stock, causing a dramatic plunge of $7.99, or 30.5%, dropping to $18.22 per share on the same day. The fallout continued on September 7, 2025, when further trial results revealed that ivonescimab performed less effectively in North American and European patients compared to their European counterparts, resulting in another sharp decline in the stock price. Following this revelation, the share price dropped by $6.54, or 25.15%, closing at $19.45 per share the next day.

The investigation led by Pomerantz aims to determine whether these developments reflect misconduct or negligence that affected investors. Shareholders who have been impacted are encouraged to reach out to Danielle Peyton at Pomerantz LLP, either via email or phone. This outreach presents an opportunity for investors to join a potential class action litigation against Summit Therapeutics.

Pomerantz LLP stands out in the legal landscape, with a history that traces back to Abraham L. Pomerantz, who is often revered as a pioneer in the field of class action lawsuits concerning securities. The firm has its offices in prominent cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, enabling it to pursue cases of corporate, securities, and antitrust class actions effectively.

Over the course of its existence, Pomerantz has recouped numerous multimillion-dollar settlements for clients, showcasing its commitment to fighting against securities fraud and corporate misconduct. As the investigation unfolds, both current and former investors in Summit Therapeutics will be monitoring the situation closely, hoping for accountability and resolution regarding their investments.

For those involved, this could mark a crucial moment in seeking justice and elucidating the truth behind the concerning developments surrounding Summit Therapeutics. Affected shareholders should remain informed and consider engaging with legal counsel to explore their options going forward.

If you are a current or former investor in Summit Therapeutics Inc. and believe you may have been impacted by these recent events, do not hesitate to reach out for assistance. The actions taken now might be pivotal in safeguarding your rights and interests.